SQI Diagnostics Inc. (V:SQD.H)

Business Focus: Advanced Medical Equipment & Technology (NEC)

Get the company report for the most recent outlook updated daily

Sep 06, 2023 07:57 am ET

Canadian Investment Regulatory Organization Trading Halt - SQD

VANCOUVER, BC, Sept. 6, 2023 /CNW/ - The following issues have been halted by CIRO

Jun 16, 2023 05:12 pm ET

SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing

TORONTO, June 16, 2023 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF) today announced that the Company's board of directors (the "Board") has received a notice of intention (the "Notice") to enforce security issued by its senior secured creditor, Pivot Financial I Limited Partnership ("Pivot"), under Section 244(1) of the Bankruptcy and Insolvency Act (the "Act").

Jun 16, 2023 05:12 pm ET

SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing

TORONTO, June 16, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF) today announced that the Company's board of directors (the "Board") has received a notice of intention (the "Notice") to enforce security issued by its senior secured creditor, Pivot Financial I Limited Partnership ("Pivot"), under Section 244(1) of the Bankruptcy and Insolvency Act (the "Act").

Jun 15, 2023 08:59 am ET

Canadian Investment Regulatory Organization Trading Halt - SQD

VANCOUVER, BC, June 15, 2023 /CNW/ - The following issues have been halted by CIRO

Jun 06, 2023 01:06 pm ET

Canadian Investment Regulatory Organization Trade Resumption - SQD

VANCOUVER, BC, June 6, 2023 /CNW/ - Trading resumes in:

Jun 06, 2023 12:39 pm ET

SQI Diagnostics Reports Internal Restructuring

TORONTO, June 6, 2023 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today announced that the Company's board of directors (the "Board") has issued layoff notices to each of Andrew Morris, the Company's Chief Executive, and Eric Brouwer, the Company's Chief Scientific Officer, in an effort to further reduce the Company's expenses. Messrs. Morris and Brouwer have advised the Board that they will resign from their positions as directors of the

Jun 06, 2023 12:39 pm ET

SQI Diagnostics Reports Internal Restructuring

TORONTO, June 6, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today announced that the Company's board of directors (the "Board") has issued layoff notices to each of Andrew Morris, the Company's Chief Executive, and Eric Brouwer, the Company's Chief Scientific Officer, in an effort to further reduce the Company's expenses. Messrs. Morris and Brouwer have advised the Board that they will resign from their positions as directors

Jun 06, 2023 09:06 am ET

Canadian Investment Regulatory Organization Trading Halt - SQD

VANCOUVER, BC, June 6, 2023 /CNW/ - The following issues have been halted by CIRO

May 30, 2023 06:17 pm ET

SQI Diagnostics Reports Second Quarter 2023 Results

TORONTO, May 30, 2023 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the second quarter ended March 31, 2022.

May 30, 2023 06:17 pm ET

SQI Diagnostics Reports Second Quarter 2023 Results

TORONTO, May 30, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the second quarter ended March 31, 2022.

May 08, 2023 05:17 pm ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND DEFERRAL OF CERTAIN INTEREST PAYMENTS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Mar 28, 2023 08:22 am ET

SQI to Focus on Development of Point of Care Products In Respiratory Health

TORONTO, March 28, 2023 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health, today announced that it is moving to strategically focus on what is now its core business: creating precision Point of Care (POC) products in respiratory health.

Mar 28, 2023 08:22 am ET

SQI to Focus on Development of Point of Care Products In Respiratory Health

TORONTO, March 28, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health, today announced that it is moving to strategically focus on what is now its core business: creating precision Point of Care (POC) products in respiratory health.

Mar 24, 2023 08:21 am ET

SQI DIAGNOSTICS ANNOUNCES PROPOSED INSIDER SALES AND WARRANT EXERCISES TO FUND COMPANY

TORONTO, March 24, 2023 /CNW/ - SQI Diagnostics Inc. (the "Company" or "SQI") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, announces that certain insiders of the Company, who are also control persons of the Company and collectively own, or exercise control or direction over, an aggregate of 75% of the issued and outstanding common shares ("Shares") in the capital of the Company (the "Majority Shareholders"), have informed the Company of their intention to sell, from time to time, up to an ag

Mar 24, 2023 08:21 am ET

SQI DIAGNOSTICS ANNOUNCES PROPOSED INSIDER SALES AND WARRANT EXERCISES TO FUND COMPANY

TORONTO, March 24, 2023 /PRNewswire/ - SQI Diagnostics Inc. (the "Company" or "SQI") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, announces that certain insiders of the Company, who are also control persons of the Company and collectively own, or exercise control or direction over, an aggregate of 75% of the issued and outstanding common shares ("Shares") in the capital of the Company (the "Majority Shareholders"), have informed the Company of their intention to sell, from time to time, up t

Mar 20, 2023 05:22 pm ET

SQI DIAGNOSTICS ANNOUNCES ISSUANCE OF PREVIOUSLY ANNOUNCED BONUS WARRANTS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Mar 13, 2023 08:17 am ET

SQI Diagnostics Announces New Capital Markets Consulting Agreement

TORONTO, March 13, 2023 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants ("Looking Glass"), pursuant to which Looking Glass will assist the Company with identifying potential new sources of up to $10 million of equity financing.

Mar 13, 2023 08:17 am ET

SQI Diagnostics Announces New Capital Markets Consulting Agreement

TORONTO, March 13, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants ("Looking Glass"), pursuant to which Looking Glass will assist the Company with identifying potential new sources of up to $10 million of equity financing.

Mar 10, 2023 07:19 am ET

SQI DIAGNOSTICS ANNOUNCES ADDITIONAL $500,000 ADVANCE UNDER PIVOT CREDIT FACILITY AND OPTION GRANTS

TORONTO, March 10, 2023 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, announces that Pivot Financial ("Pivot") has agreed to advance (the "New Advance") an additional $500,000 to SQI under the terms of SQI's existing secured credit facility (the "Credit Facility") with Pivot dated February 11, 2022, as amended from time to time, pursuant to an amending agreement dated the date hereof (the "Pivot Amendment"). The New Advance will be secured

Mar 03, 2023 07:17 am ET

Four Diagnostic Products in the Pipeline at SQI

TORONTO, March 3, 2023 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, today announced it is developing three diagnostic products based on University Health Network (UHN) innovations and is exploring an initiative with Owlstone Medical and UHN on a fourth diagnostic product. The first three products include RALI-Dx™ IL-6 Severity Triage Test, TORdx™ LUNG, and RALI-fast™ IL-6 Severity Triage POC Test, as well as a preliminary study of Owlstone Medical's Breathe Biop

Mar 01, 2023 05:50 pm ET

SQI Diagnostics Reports First Quarter 2023 Results

TORONTO, March 1, 2023 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the first quarter ended December 31, 2022.

Feb 28, 2023 06:22 pm ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Feb 06, 2023 07:17 am ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND DEFERRAL OF CERTAIN INTEREST PAYMENTS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jan 30, 2023 10:55 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2022 Results

Revenue Up 800% Year-over-Year

Jan 30, 2023 10:55 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2022 Results

Revenue Up 800% Year-over-Year

Jan 18, 2023 07:17 am ET

SQI installs two RALI-DX systems in Toronto hospitals to fight the growing respiratory health crisis in Emergency Departments

TORONTO, Jan. 18, 2023 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, today announced that its Rapid Acute Lung Injury Diagnostic (RALI-Dx™) IL-6 Severity Triage Test has been installed in two University Health Network (UHN) hospitals in Toronto to use as a clinical aid to help assess respiratory patients in the Emergency Department(ED) and as part of a study to help fight the growing respiratory health crisis in EDs.

Jan 18, 2023 07:17 am ET

SQI installs two RALI-DX systems in Toronto hospitals to fight the growing respiratory health crisis in Emergency Departments

TORONTO, Jan. 18, 2023 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, today announced that its Rapid Acute Lung Injury Diagnostic (RALI-Dx™) IL-6 Severity Triage Test has been installed in two University Health Network (UHN) hospitals in Toronto to use as a clinical aid to help assess respiratory patients in the Emergency Department(ED) and as part of a study to help fight the growing respiratory health crisis in EDs.

Dec 16, 2022 04:17 pm ET

SQI Diagnostics Inc. Closes Second Tranche of Private Placement

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Dec 02, 2022 07:19 am ET

SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Nov 24, 2022 04:19 pm ET

SQI Diagnostics Inc. Announces Private Placement of $1.0 Million

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Nov 24, 2022 07:29 am ET

DISPOSITION OF COMMON SHARES OF SQI DIAGNOSTICS INC.

/NOT FOR DISSEMINATION IN THE UNITED STATES OR OVER UNITED STATES NEWSWIRE SERVICES/

Nov 24, 2022 07:29 am ET

DISPOSITION OF COMMON SHARES OF SQI DIAGNOSTICS INC.

/NOT FOR DISSEMINATION IN THE UNITED STATES OR OVER UNITED STATES NEWSWIRE SERVICES/

Nov 10, 2022 07:17 am ET

SQI Diagnostics Secures Up To $2 Million in FedDev Ontario Funding

Funding to be used to Scale-up and Support Commercialization of SQI Products

Nov 10, 2022 07:17 am ET

SQI Diagnostics Secures Up To $2 Million in FedDev Ontario Funding

Funding to be used to Scale-up and Support Commercialization of SQI Products

Oct 19, 2022 05:17 pm ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND ANNOUNCES DEFERRAL OF CERTAIN INTEREST PAYMENTS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Oct 19, 2022 05:17 pm ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND ANNOUNCES DEFERRAL OF CERTAIN INTEREST PAYMENTS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Oct 18, 2022 02:25 pm ET

The Power Play by The Market Herald Releases New Interviews with SQI Diagnostics, Silver Bullet Mines, G Mining Ventures and Nextech AR Solutions Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / October 18, 2022 / The Power Play by The Market Herald has announced the release of new interviews with SQI Diagnostics, Silver Bullet Mines, G Mining Ventures and Nextech AR Solutions discussing their latest news.

Oct 17, 2022 08:17 am ET

/C O R R E C T I O N from Source -- SQI Diagnostics Inc./

In the news release, SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test, issued 17-Oct-2022 by SQI Diagnostics Inc. over CNW, the company advises that the content has been updated. The complete, revised copy follows:

Oct 17, 2022 08:17 am ET

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

TORONTO, Oct. 17, 2022 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, today announced it has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx™) IL-6 Severity Triage Test. RALI-Dx™ is the first interleukin-6 (IL-6) diagnostic test approved in Canada, and its turnaround time of less than an hour is developed to fill an important and unmet public health need.

Oct 17, 2022 08:17 am ET

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

TORONTO, Oct. 17, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, today announced it has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx™) IL-6 Severity Triage Test. RALI-Dx™ is the first interleukin-6 (IL-6) diagnostic test approved in Canada, and its turnaround time of less than an hour is developed to fill an important and unmet public health need.

Aug 31, 2022 08:30 am ET

SQI Diagnostics Announces Grant of Stock Options

TORONTO, Aug. 31, 2022 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests announced that effective August 26, 2022, it has granted an aggregate of 2,877,500 stock options ("Options") to certain employees and officers of the Company under the Company's amended and restated stock option plan (the "Plan"). The goal of the grant of Options is to align the interests of the Company's employees, officers and directors with those of shareholders. The Options were granted at an

Aug 31, 2022 08:30 am ET

SQI Diagnostics Announces Grant of Stock Options

TORONTO, Aug. 31, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests announced that effective August 26, 2022, it has granted an aggregate of 2,877,500 stock options ("Options") to certain employees and officers of the Company under the Company's amended and restated stock option plan (the "Plan"). The goal of the grant of Options is to align the interests of the Company's employees, officers and directors with those of shareholders. The Options were granted

Aug 29, 2022 08:30 am ET

SQI Diagnostics Reports Third Quarter 2022 Results

New Business Contributes $1.1M in Revenue

Aug 29, 2022 08:30 am ET

SQI Diagnostics Reports Third Quarter 2022 Results

New Business Contributes $1.1M in Revenue

Jun 20, 2022 08:30 am ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Jun 20, 2022 08:30 am ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Jun 17, 2022 06:41 pm ET

SQI Diagnostics Inc. Announces Closing of $4.05 Million Debt Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jun 17, 2022 06:41 pm ET

SQI Diagnostics Inc. Announces Closing of $4.05 Million Debt Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

May 31, 2022 02:50 pm ET

The Power Play by The Market Herald Releases New Interviews with SQI Diagnostics, Hank Payments, CareSpan Health, and HIRE Technologies

VANCOUVER, BC / ACCESSWIRE/ May 31, 2022 / The Power Play by The Market Herald has announced the release of new interviews with SQI Diagnostics, Hank Payments, CareSpan Health, and HIRE Technologies on their latest news.

May 26, 2022 05:00 pm ET

SQI Diagnostics Reports Second Quarter 2022 Results

New Business Contributes $5.5M in Revenue

May 26, 2022 05:00 pm ET

SQI Diagnostics Reports Second Quarter 2022 Results

New Business Contributes $5.5M in Revenue

Apr 13, 2022 04:23 pm ET

SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Mar 25, 2022 04:03 pm ET

SQI Diagnostics Inc. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT

TORONTO, March 25, 2022 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, announced today that Company CEO Andrew Morris has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Mar 25, 2022 04:03 pm ET

SQI Diagnostics Inc. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT

TORONTO, March 25, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, announced today that Company CEO Andrew Morris has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Mar 03, 2022 03:30 pm ET

The Power Play by The Market Herald Releases New Interviews With Hank Payments, Mobi724, Ayurcann Holdings, and SQI Diagnostic

VANCOUVER, BC / ACCESSWIRE / March 3, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Hank Payments, Mobi724, Ayurcann Holdings, and SQI Diagnostics on their latest news.

Mar 03, 2022 08:07 am ET

New York State Approves SQI Diagnostics' EXACT COVID-19 Antibody Assay

-- Conditional Approval Makes Quick, Precise Test for Presence of Antibodies to SARS-CoV-2 Available in the US --

Mar 03, 2022 08:07 am ET

New York State Approves SQI Diagnostics' EXACT COVID-19 Antibody Assay

-- Conditional Approval Makes Quick, Precise Test for Presence of Antibodies to SARS-CoV-2 Available in the US --

Feb 28, 2022 06:01 pm ET

SQI Diagnostics Reports First Quarter 2022 Results

TORONTO, Feb. 28, 2022 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) ( OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported their financial and operational results for the first quarter for fiscal year ending September 30, 2022.

Feb 28, 2022 06:01 pm ET

SQI Diagnostics Reports First Quarter 2022 Results

TORONTO, Feb. 28, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) ( OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported their financial and operational results for the first quarter for fiscal year ending September 30, 2022.

Feb 14, 2022 08:08 am ET

SQI DIAGNOSTICS COMPLETES ACQUISITION OF PRECISION BIOMONITORING'S HUMAN DIAGNOSTIC TESTING BUSINESS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Jan 26, 2022 04:48 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2021 Results

TORONTO, Jan. 26, 2022 /CNW/ - SQI Diagnostics Inc. ('SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2021.

Jan 26, 2022 04:48 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2021 Results

TORONTO, Jan. 26, 2022 /PRNewswire/ - SQI Diagnostics Inc. ('SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2021.

Jan 24, 2022 07:47 am ET

SQI Diagnostics Inc Signs MOU with UK-Based Owlstone Medical

Companies Plan to Commercialize Breath-Based Detection of Lung Infection and Transplant Rejection

Jan 13, 2022 08:15 am ET

SQI Diagnostics Inc Congratulates its Partner UHN for Winning $24 Million Award from Government of Canada

The New Frontiers in Research Fund – Transformation Award Will Support World-Leading Innovation in Organ Transplant.

Jan 13, 2022 08:15 am ET

SQI Diagnostics Inc Congratulates its Partner UHN for Winning $24 Million Award from Government of Canada

The New Frontiers in Research Fund – Transformation Award Will Support World-Leading Innovation in Organ Transplant.

Jan 10, 2022 03:44 pm ET

IIROC Trading Resumption - SQD

VANCOUVER, BC, Jan. 10, 2022 /CNW/ - Trading resumes in:

Jan 10, 2022 02:39 pm ET

SQI ENTERS DEFINITIVE AGREEMENT TO ACQUIRE PRECISION BIOMONITORING'S HUMAN DIAGNOSTIC TESTING BUSINESS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Jan 10, 2022 08:26 am ET

IIROC Trading Halt - SQD

VANCOUVER, BC, Jan. 10, 2022 /CNW/ - The following issues have been halted by IIROC:

Nov 08, 2021 05:08 pm ET

SQI Diagnostics Inc. Closes Second and Final Tranche of Private Placement

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Nov 01, 2021 05:13 pm ET

SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Oct 19, 2021 06:08 pm ET

SQI Diagnostics Inc. Responds to Change in FDA Priorities in Emergency Use Authorization

TORONTO, Oct. 19, 2021 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today responded to a recent shift in US Food and Drug Administration (FDA) priorities around Emergency Use Authorization (EUA).

Oct 19, 2021 06:08 pm ET

SQI Diagnostics Inc. Responds to Change in FDA Priorities in Emergency Use Authorization

TORONTO, Oct. 19, 2021 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today responded to a recent shift in US Food and Drug Administration (FDA) priorities around Emergency Use Authorization (EUA).

Sep 13, 2021 08:17 am ET

SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options

TORONTO, Sept. 13, 2021 /CNW/ - SQI Diagnostics, Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that the Company's board of directors has appointed Andrew Morris as Chief Executive Officer of the Company effective September 11, 2021. Mr. Morris is currently a director of the Company.

Sep 13, 2021 08:17 am ET

SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options

TORONTO, Sept. 13, 2021 /PRNewswire/ - SQI Diagnostics, Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that the Company's board of directors has appointed Andrew Morris as Chief Executive Officer of the Company effective September 11, 2021. Mr. Morris is currently a director of the Company.

Aug 30, 2021 08:20 am ET

SQI Diagnostics Inc. Announces Grant of Stock Options

TORONTO, Aug. 30, 2021 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective August 27, 2021, it has granted an aggregate of 3,385,000 stock options ("Options") to a consultant and certain employees and officers of the Company under the Company's amended and restated stock option plan (the "Plan"). The goal of the grant of Options is to align the interests of the Company's employees

Aug 30, 2021 08:20 am ET

SQI Diagnostics Inc. Announces Grant of Stock Options

TORONTO, Aug. 30, 2021 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective August 27, 2021, it has granted an aggregate of 3,385,000 stock options ("Options") to a consultant and certain employees and officers of the Company under the Company's amended and restated stock option plan (the "Plan"). The goal of the grant of Options is to align the interests of the Company's em

Aug 18, 2021 09:13 am ET

SQI Diagnostics Reports Third Quarter 2021 Results

TORONTO, Aug. 18, 2021 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the third quarter of fiscal year 2021, ended June 30th, 2021.

Aug 18, 2021 09:13 am ET

SQI Diagnostics Reports Third Quarter 2021 Results

TORONTO, Aug. 18, 2021 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the third quarter of fiscal year 2021, ended June 30th, 2021.

Jul 23, 2021 04:30 pm ET

FDA Stops Emergency Use Authorization Review of SQI Diagnostics RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients

FDA cites de-prioritization due to high volume of EUA reviews; recommends other approval pathway for this test

Jul 23, 2021 04:30 pm ET

FDA Stops Emergency Use Authorization Review of SQI Diagnostics RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients

FDA cites de-prioritization due to high volume of EUA reviews; recommends other approval pathway for this test

Jul 15, 2021 08:22 pm ET

SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's COVID-19 HOME Antibody Test

TORONTO, July 15, 2021 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI") and AZOVA Inc., creator of the world's most comprehensive digital health network for COVID-19 testing and vaccination management, today announced the signing of an agreement that subject to an approval by the Food & Drug Administration (FDA), will allow AZOVA to sell and distribute SQI's COVID-19 HOME Antibody Test to its customer base of airlines, wholesal

Jul 15, 2021 08:22 pm ET

SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's COVID-19 HOME Antibody Test

TORONTO, July 15, 2021 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI") and AZOVA Inc., creator of the world's most comprehensive digital health network for COVID-19 testing and vaccination management, today announced the signing of an agreement that subject to an approval by the Food & Drug Administration (FDA), will allow AZOVA to sell and distribute SQI's COVID-19 HOME Antibody Test to its customer base of airlines, w

Jun 15, 2021 03:00 pm ET

SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders

TORONTO, June 15, 2021 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announces that certain insiders of the Company, who are control persons (the "Control Persons"), have exercised 19,687,504 common share (each, a "Share") purchase warrants of the Company (the "Insider Warrants") for aggregate gross proceeds of approximately $3.9 million. Of the Insider Warrants exercised, 19,687,504 Insider Warrants were

Jun 15, 2021 03:00 pm ET

SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders

TORONTO, June 15, 2021 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announces that certain insiders of the Company, who are control persons (the "Control Persons"), have exercised 19,687,504 common share (each, a "Share") purchase warrants of the Company (the "Insider Warrants") for aggregate gross proceeds of approximately $3.9 million. Of the Insider Warrants exercised, 19,687,504 Insider Warrant

May 27, 2021 08:00 pm ET

SQI Diagnostics Inc. Announces Grant of Stock Options

TORONTO, May 27, 2021 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective May 27, 2021, it has granted an aggregate of 2,409,717 stock options ("Options") to a consultant and certain employees and officers of the Company under the Company's amended and restated stock option plan (the "Plan"). The goal of the grant of Options is to align the interests of the Company's employees, officers

May 21, 2021 07:21 pm ET

SQI Diagnostics Reports Second Quarter 2021 Results and Announces Departure of CEO and Appointment of Interim CEO

TORONTO, May 21, 2021 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announced today that due to the unfortunate continued travel restrictions and inability to cross the US/Canadian border since the COVID-19 pandemic began, including the inability to predict when travel restrictions will end, Mr. Robert Chioini, Chief Executive Officer, is leaving the Company to pursue other opportunitie

Apr 13, 2021 09:15 am ET

SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant

Grant to Move New Infection-Testing Technology from Lab to Market

Apr 01, 2021 08:00 am ET

SQI Diagnostics Submits RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization

Test Designed to Assist in Identifying Severe Inflammatory Response in Patients with Confirmed COVID-19 Illness

Mar 08, 2021 08:11 am ET

SQI Diagnostics Receives $2.3 Million in Funds from Shareholder Exercise of Securities

Company Continues to Improve Gross Cash Position to Execute Business Plan

Mar 01, 2021 05:30 pm ET

SQI Diagnostics Reports First Quarter 2021 Results

TORONTO, March 1, 2021 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the first quarter of fiscal year 2021, ended December 31, 2020.

Feb 18, 2021 03:03 pm ET

SQI Diagnostics Announces New Corporate Website

New Website Provides Essential Information on Company's Strategic Initiative

Feb 18, 2021 03:03 pm ET

SQI Diagnostics Announces New Corporate Website

New Website Provides Essential Information on Company's Strategic Initiative

Feb 10, 2021 06:30 am ET

SQI Diagnostics Announces Proposed Insider Sales and Warrant Exercises to Fund Company

Company Expects to Use Proceeds for Clinical Development and Commercialization Efforts

Jan 27, 2021 04:01 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2020 Results

TORONTO, Jan. 27, 2021 /CNW/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2020.

Jan 27, 2021 04:01 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2020 Results

TORONTO, Jan. 27, 2021 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2020.

Jan 25, 2021 07:05 am ET

SQI Diagnostics Announces Patient Enrollment Begins for Its COVID-19 HOME Antibody Test Clinical Study

Company Intends to Use Patient Data for Emergency Use Authorization (EUA) Submission to U.S. FDA

Jan 25, 2021 07:05 am ET

SQI Diagnostics Announces Patient Enrollment Begins for Its COVID-19 HOME Antibody Test Clinical Study

Company Intends to Use Patient Data for Emergency Use Authorization (EUA) Submission to U.S. FDA

Dec 31, 2020 07:29 pm ET

Acquisition of Common Shares of SQI Diagnostics Inc.

/NOT FOR DISSEMINATION IN THE UNITED STATES OR OVER UNITED STATES NEWSWIRE SERVICES/

Dec 31, 2020 07:20 pm ET

Acquisition of Common Shares of SQI Diagnostics Inc.

/NOT FOR DISSEMINATION IN THE UNITED STATES OR OVER UNITED STATES NEWSWIRE SERVICES/

Dec 30, 2020 04:01 pm ET

SQI Diagnostics Announces $4 Million Funding via Warrant Exercise by Insiders

Company will Use Proceeds for Clinical Development and Commercialization Efforts

Dec 30, 2020 04:01 pm ET

SQI Diagnostics Announces $4 Million Funding via Warrant Exercise by Insiders

Company will Use Proceeds for Clinical Development and Commercialization Efforts

Oct 26, 2020 07:30 am ET

SQI Diagnostics Updates Clinical Progress on Novel COVID-19 Tests Under Development for U.S. FDA Regulatory Submission

Company Confirms COVID-19 Antibody Home Test and Two Severity Triage Tests can be Submitted to U.S. FDA Under Emergency Use Authorization

Oct 26, 2020 07:30 am ET

SQI Diagnostics Updates Clinical Progress on Novel COVID-19 Tests Under Development for U.S. FDA Regulatory Submission

Company Confirms COVID-19 Antibody Home Test and Two Severity Triage Tests can be Submitted to U.S. FDA Under Emergency Use Authorization

Oct 20, 2020 09:15 am ET

SQI Diagnostics and McMaster University Researchers Create New Technology to Better Measure Severity of COVID-19 Disease

Exclusive Nanotechnology Enables Precise Detection of Critical "Cytokine Storm" Markers

Oct 20, 2020 09:15 am ET

SQI Diagnostics and McMaster University Researchers Create New Technology to Better Measure Severity of COVID-19 Disease

Exclusive Nanotechnology Enables Precise Detection of Critical "Cytokine Storm" Markers

Sep 09, 2020 09:24 am ET

SQI Diagnostics Expanding Business into Rapid Diagnostic Testing Market

Novel Diagnostics Target Organ Transplant, Autoimmune Disease and Serological Testing, Including Two Rapid Tests for COVID-19

Sep 09, 2020 08:15 am ET

SQI Diagnostics Expanding Business into Rapid Diagnostic Testing Market

SQI Diagnostics, Inc. (TSX-V: SQD; OTCQX-US: SQIDF), a precision medicine company that discovers, develops, manufactures and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today...

Aug 27, 2020 09:15 am ET

SQI Diagnostics Reports Third Quarter 2020 Results

TORONTO, Aug. 27, 2020 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF), today reported its financial and operational results for the three and nine months ended June 30, 2020.

Aug 27, 2020 08:48 am ET

SQI Diagnostics Inc. Announces Stock Option Grant

TORONTO, Aug. 27, 2020 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective August 26, 2020, it has granted (the "Grants") 1,807,797 stock options ("Options") under the Company' stock option plan, as amended (the "Plan"). The goal of the grant of the Options is to align the interests of the Company's employees, officers and directors with those of shareholders. An aggregate of 510,000 o

Aug 18, 2020 09:09 am ET

IIROC Trading Resumption - SQD

VANCOUVER, BC, Aug. 18, 2020 /CNW/ - Trading resumes in:

Aug 18, 2020 09:07 am ET

SQI Diagnostics Appoints Rob Chioini as Chief Executive Officer, Grants Options and Amends Stock Option Plan

SQI Diagnostics, Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that the...

Aug 18, 2020 08:49 am ET

SQI Diagnostics Appoints Rob Chioini as Chief Executive Officer, Grants Options and Amends Stock Option Plan

Accomplished Medical Device and Pharma Executive Brings Proven Record of Building Value in Life Science Companies

Aug 18, 2020 08:44 am ET

IIROC Trading Halt - SQD

VANCOUVER, BC, Aug. 18, 2020 /CNW/ - The following issues have been halted by IIROC:

Jul 03, 2020 07:45 am ET

SQI Diagnostics Inc. Announces Warrant Exercise by Insiders

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA./

May 28, 2020 04:15 pm ET

SQI Diagnostics Inc. Announces Director Changes

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

May 28, 2020 09:15 am ET

SQI Diagnostics Reports Second Quarter 2020 Results

TORONTO, May 28, 2020 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three and six months ended March 31, 2020.

May 28, 2020 09:15 am ET

SQI Diagnostics Reports Second Quarter 2020 Results

TORONTO, May 28, 2020 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three and six months ended March 31, 2020.

May 05, 2020 09:15 am ET

SQI Diagnostics completes sale of sqid-X(TM) diagnostic system to University of Buffalo

The first commercial sqid-X system sale to be used to triage COVID-19 patients in New York state

May 05, 2020 09:15 am ET

SQI Diagnostics completes sale of sqid-X(TM) diagnostic system to University of Buffalo

The first commercial sqid-X system sale to be used to triage COVID-19 patients in New York state

Apr 01, 2020 06:08 pm ET

SQI Diagnostics Inc. Announces Stock Option Grant

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Mar 24, 2020 05:00 pm ET

SQI Diagnostics Inc. to hold Annual and Special Meeting of Shareholders by Conference Call; Announces Management Changes

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Mar 24, 2020 09:15 am ET

One-hour coronavirus triage test developed by SQI Diagnostics to receive funding from University Health Network

Grant of $1 million used to finalize development and deployment of existing assay to triage coronavirus patients

Mar 24, 2020 09:15 am ET

One-hour coronavirus triage test developed by SQI Diagnostics to receive funding from University Health Network

Grant of $1 million used to finalize development and deployment of existing assay to triage coronavirus patients

Mar 10, 2020 09:15 am ET

SQI Diagnostics Inc. Announces Stock Option Grant

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Mar 05, 2020 04:05 pm ET

SQI Diagnostics Inc. Closes Second and Final Tranche of Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Feb 27, 2020 08:15 am ET

SQI Diagnostics Reports First Quarter 2020 Results

TORONTO, Feb. 27, 2020 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three months ended December 31, 2019.

Feb 20, 2020 06:45 am ET

SQI Diagnostics Inc. Announces Extension of Debentures and Additional Debt Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Feb 18, 2020 06:30 am ET

SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jan 31, 2020 06:45 am ET

SQI Diagnostics Inc. Announces Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jan 30, 2020 06:45 am ET

SQI Diagnostics Inc. Announces Extension of Debentures and Additional Debt Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jan 16, 2020 07:45 am ET

University Health Network Completes Validation of SQI Diagnostics' TORdx LUNG™ Organ Assessment Assay

Major milestone in commercialization of precision medicine technology achieved

Dec 11, 2019 04:30 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2019 Results and Management Changes

TORONTO, Dec. 11, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2019.

Dec 04, 2019 08:56 am ET

SQI Diagnostics to Announce Fourth Quarter and Fiscal 2019 Results

TORONTO, Dec. 4, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the fourth quarter and year ended September 30, 2019, at 5:30 p.m. ET Wednesday, December 11, 2019. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday, December 12, 2019, at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Oct 22, 2019 05:25 pm ET

SQI Diagnostics Inc. Announces Closing of Second and Final Tranche of Private Placement

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA./

Sep 25, 2019 05:05 pm ET

SQI Diagnostics Inc. Announces Closing of Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Sep 16, 2019 08:00 am ET

SQI Diagnostics Inc. Announces Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Aug 28, 2019 08:00 am ET

SQI Diagnostics Reports Third Quarter 2019 Results

TORONTO, Aug. 28, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three and nine months ended June 30, 2019.

Aug 28, 2019 08:00 am ET

SQI Diagnostics Reports Third Quarter 2019 Results

TORONTO, Aug. 28, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three and nine months ended June 30, 2019.

Aug 20, 2019 02:37 pm ET

SQI Diagnostics to Announce Third Quarter 2019 Results

TORONTO, Aug. 20, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and nine months ended June 30, 2019, at 8:00 a.m. EDT Wednesday, August 28, 2019. President and CEO, Andrew Morris, along with Company management, will host a conference call on Wednesday, August 28, 2019, at 10:00 a.m. EDT to review financial results and discuss business developments for the period.

Aug 20, 2019 02:37 pm ET

SQI Diagnostics to Announce Third Quarter 2019 Results

TORONTO, Aug. 20, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and nine months ended June 30, 2019, at 8:00 a.m. EDT Wednesday, August 28, 2019. President and CEO, Andrew Morris, along with Company management, will host a conference call on Wednesday, August 28, 2019, at 10:00 a.m. EDT to review financial results and discuss business developments for the period.

Jul 15, 2019 07:45 am ET

SQI Diagnostics Inc. Closes Previously Announced Private Placement

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jul 02, 2019 09:00 am ET

SQI Diagnostics Inc. Announces Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jun 18, 2019 09:00 am ET

UHN and SQI Diagnostics Successfully Test New Technology to Assess Lung Health During Transplant

New procedure reduces testing time by 70%, leading to better patient outcomes

Jun 03, 2019 09:00 am ET

SQI Diagnostics Announces Stock Option Grant

TORONTO, June 3, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective May 21, 2019, they have granted 3,199,728 stock options as part of a Company-wide long-term incentive plan. The goal of the grant is to align the interest of all employees with those of shareholders. 1,835,850 options have been granted to four officers, one of whom is also a director. Independent directors did not r

May 16, 2019 08:00 am ET

SQI Diagnostics Reports Second Quarter 2019 Results

TORONTO, May 16, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three and six months ended March 31, 2019.

May 16, 2019 08:00 am ET

SQI Diagnostics Reports Second Quarter 2019 Results

TORONTO, May 16, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three and six months ended March 31, 2019.

May 02, 2019 09:07 am ET

SQI Diagnostics to Announce Second Quarter 2019 Results

TORONTO, May 2, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2019 at 8:00 a.m. ET Thursday, May 16, 2019. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday, May 16, 2019 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

May 02, 2019 09:07 am ET

SQI Diagnostics to Announce Second Quarter 2019 Results

TORONTO, May 2, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2019 at 8:00 a.m. ET Thursday, May 16, 2019. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday, May 16, 2019 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Mar 11, 2019 09:00 am ET

SQI Diagnostics Inc. Closes Second and Final Tranche of Private Placement

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Mar 04, 2019 08:00 am ET

SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Feb 28, 2019 07:00 am ET

SQI Diagnostics Reports First Quarter 2019 Results

TORONTO, Feb. 28, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three months ended December 31, 2018.

Feb 28, 2019 07:00 am ET

SQI Diagnostics Reports First Quarter 2019 Results

TORONTO, Feb. 28, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three months ended December 31, 2018.

Feb 20, 2019 08:00 am ET

SQI Diagnostics Inc. Announces Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Feb 19, 2019 03:55 pm ET

SQI Diagnostics to Announce First Quarter 2019 Results

TORONTO, Feb. 19, 2019 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three months ended December 31, 2018 at 8:00 a.m. ET Thursday, February 28, 2019. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday, February 28, 2019 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Feb 19, 2019 03:55 pm ET

SQI Diagnostics to Announce First Quarter 2019 Results

TORONTO, Feb. 19, 2019 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three months ended December 31, 2018 at 8:00 a.m. ET Thursday, February 28, 2019. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday, February 28, 2019 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Feb 04, 2019 08:00 am ET

SQI partners with Toronto's University Health Network on multiplexed testing to improve the success of organ transplantation

A multiplexed test could aid in doctors assessment of suitability of donor lungs for transplant Collaboration with Dr. Shaf Keshavjee at UHN's Toronto Lung Transplant Program, the largest lung transplant program in the world TORONTO, Feb. 4, 2019 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), today announced two research and development agreements with University Health Network (UHN) to create and license rapid multiplexed protein assays and a point-of-care (POC) diagnostic device that will help transplant surgeons assess the suitability of lungs and other organs for transplanta

Feb 04, 2019 08:00 am ET

SQI partners with Toronto's University Health Network on multiplexed testing to improve the success of organ transplantation

A multiplexed test could aid in doctors assessment of suitability of donor lungs for transplant Collaboration with Dr. Shaf Keshavjee at UHN's Toronto Lung Transplant Program, the largest lung transplant program in the world TORONTO, Feb. 4, 2019 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), today announced two research and development agreements with University Health Network (UHN) to create and license rapid multiplexed protein assays and a point-of-care (POC) diagnostic device that will help transplant surgeons assess the suitability of lungs and other organs for tran

Jan 28, 2019 08:00 am ET

SQI Diagnostics' Partner Launches Two New Direct-to-Consumer Tests

TORONTO, Jan. 28, 2019 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announces two new product launches within the imaware™ family of at-home tests by its partner, Microdrop. The new tests, which are now available for purchase, measure markers for rheumatoid arthritis and a test to monitor already-diagnosed celiac disease patients, a complement to the previously announced celiac screening test.

Jan 28, 2019 08:00 am ET

SQI Diagnostics' Partner Launches Two New Direct-to-Consumer Tests

TORONTO, Jan. 28, 2019 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announces two new product launches within the imaware™ family of at-home tests by its partner, Microdrop. The new tests, which are now available for purchase, measure markers for rheumatoid arthritis and a test to monitor already-diagnosed celiac disease patients, a complement to the previously announced celiac screening test.

Dec 11, 2018 04:00 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2018 Results

TORONTO, Dec. 11, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2018.

Dec 11, 2018 04:00 pm ET

SQI Diagnostics Reports Fourth Quarter and Fiscal 2018 Results

TORONTO, Dec. 11, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2018.

Dec 10, 2018 10:56 am ET

SQI Diagnostics' Direct-to-Consumer Partner Launches At-Home Celiac Disease Awareness Test

TORONTO, Dec. 10, 2018 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announces the launch of the imaware™ at-home test for celiac disease by its partner, Microdrop. imaware™ is a pioneering at-home health testing platform that focuses on patient empowerment by providing accurate and actionable at-home disease screening. As of today, the imaware™ at-home test for celiac disease developed alongside Microdro

Dec 10, 2018 10:56 am ET

SQI Diagnostics' Direct-to-Consumer Partner Launches At-Home Celiac Disease Awareness Test

TORONTO, Dec. 10, 2018 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announces the launch of the imaware™ at-home test for celiac disease by its partner, Microdrop. imaware™ is a pioneering at-home health testing platform that focuses on patient empowerment by providing accurate and actionable at-home disease screening. As of today, the imaware™ at-home test for celiac disease developed alongside M

Dec 04, 2018 10:30 am ET

SQI Diagnostics to Extend Warrant Expiry

TORONTO, Dec. 4, 2018 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announced that it intends to extend the expiry of 7,630,945 outstanding common share purchase warrants ("the Warrants") of the Company, which were issued in connection with the Company's December 2015 private placement financing. The extension of the warrants was approved by members of the Board of Directors who are independent of this se

Dec 04, 2018 10:30 am ET

SQI Diagnostics to Extend Warrant Expiry

TORONTO, Dec. 4, 2018 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announced that it intends to extend the expiry of 7,630,945 outstanding common share purchase warrants ("the Warrants") of the Company, which were issued in connection with the Company's December 2015 private placement financing. The extension of the warrants was approved by members of the Board of Directors who are independent of

Nov 27, 2018 03:39 pm ET

SQI Diagnostics to Announce Fourth Quarter and Fiscal 2018 Results

TORONTO, Nov. 27, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the fourth quarter and fiscal year ended September 30, 2018 at 5:00 p.m. ET Tuesday, December 11, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Wednesday, December 12, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Nov 27, 2018 03:39 pm ET

SQI Diagnostics to Announce Fourth Quarter and Fiscal 2018 Results

TORONTO, Nov. 27, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the fourth quarter and fiscal year ended September 30, 2018 at 5:00 p.m. ET Tuesday, December 11, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Wednesday, December 12, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Aug 27, 2018 09:00 am ET

SQI Diagnostics Inc. Closes Second and Final Tranche of Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

Aug 17, 2018 03:14 pm ET

SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Aug 16, 2018 05:00 pm ET

SQI Diagnostics Reports Third Quarter 2018 Results

growth in recurring revenues from kit sales

Aug 16, 2018 05:00 pm ET

SQI Diagnostics Reports Third Quarter 2018 Results

growth in recurring revenues from kit sales

Aug 07, 2018 04:02 pm ET

SQI Diagnostics to Announce Third Quarter 2018 Results

TORONTO, Aug. 7, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and nine months ended June 30, 2018 at 5:00 p.m. ET Thursday, August 16, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Friday, August 17, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Aug 07, 2018 04:02 pm ET

SQI Diagnostics to Announce Third Quarter 2018 Results

TORONTO, Aug. 7, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and nine months ended June 30, 2018 at 5:00 p.m. ET Thursday, August 16, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Friday, August 17, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Jul 31, 2018 08:30 am ET

SQI Diagnostics Inc. Announces Private Placement with Insider Participation

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/

Jul 30, 2018 08:30 am ET

SQI Diagnostics gains momentum achieving recurring revenues with major new commercial milestones

Installations, test volume, client acquisition and recurring revenues all demonstrate continued commercial progress.

Jul 30, 2018 08:30 am ET

SQI Diagnostics gains momentum achieving recurring revenues with major new commercial milestones

Installations, test volume, client acquisition and recurring revenues all demonstrate continued commercial progress.

Jul 04, 2018 04:30 pm ET

SQI Diagnostics to Extend Warrant Expiry

TORONTO, July 4, 2018 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI" or the "Company"), today announced that it intends to extend the expiry of 5,330,000 outstanding common share purchase warrants ("the Warrants") of the Company, which were issued in connection with the Company's July 2015 private placement financing. The extension of the warrants was approved by members of the Board of Directors who are independent of this series

Jul 04, 2018 04:30 pm ET

SQI Diagnostics to Extend Warrant Expiry

Jun 13, 2018 10:00 am ET

SQI appoints Eric Zwisler, a world leader in the healthcare market, to its Board of Directors

Eric Zwisler was most recently Chair of Cardinal Health China and CEO of its multi-billion dollar Chinese operations which he founded in 1994.

Jun 13, 2018 10:00 am ET

SQI appoints Eric Zwisler, a world leader in the healthcare market, to its Board of Directors

Eric Zwisler was most recently Chair of Cardinal Health China and CEO of its multi-billion dollar Chinese operations which he founded in 1994.

Jun 12, 2018 12:32 pm ET

SQI Diagnostics to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel

TORONTO, ON / ACCESSWIRE / June 12, 2018 / SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF), will be presenting at this year's MicroCap Conference on June 21st in Toronto, Canada.

May 10, 2018 05:15 pm ET

SQI Diagnostics Reports Second Quarter 2018 Results

growth in recurring revenues from kit sales

May 10, 2018 05:15 pm ET

SQI Diagnostics Reports Second Quarter 2018 Results

growth in recurring revenues from kit sales

May 10, 2018 05:00 pm ET

SQI Diagnostics and Microdrop Launch Revolutionary Disease Awareness Tests for Direct-to-Consumer Market

TORONTO, May 10, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI"), and Microdrop LLC, a direct to consumer healthcare company focused on next generation digital and technology solutions that increase patient awareness to life-altering conditions, today announced a commercial agreement to serve the rapidly-growing direct-to-consumer healthcare diagnostic testing market valued at $173M (USD) in 2016 and

May 10, 2018 05:00 pm ET

SQI Diagnostics and Microdrop Launch Revolutionary Disease Awareness Tests for Direct-to-Consumer Market

TORONTO, May 10, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI"), and Microdrop LLC, a direct to consumer healthcare company focused on next generation digital and technology solutions that increase patient awareness to life-altering conditions, today announced a commercial agreement to serve the rapidly-growing direct-to-consumer healthcare diagnostic testing market valued at $173M (USD) in 20

Apr 27, 2018 09:56 am ET

SQI Diagnostics to Announce Second Quarter 2018 Results

TORONTO, April 27, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2018 at 5:00 p.m. ET Thursday, May 10, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Friday, May 11, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Apr 27, 2018 09:56 am ET

SQI Diagnostics to Announce Second Quarter 2018 Results

TORONTO, April 27, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2018 at 5:00 p.m. ET Thursday, May 10, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Friday, May 11, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Mar 09, 2018 09:23 am ET

SQI Diagnostics Announces Stock Option Grant

TORONTO, March 9, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective March 5, 2018, they have granted 4,130,770 stock options as part of a Company-wide long-term incentive plan. The goal of the grant is to align the interest of all employees with those of shareholders. 2,381,944 options have been granted to four officers, one of whom is also a director. Independent directors did not r

Mar 09, 2018 09:23 am ET

SQI Diagnostics Announces Stock Option Grant

TORONTO, March 9, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective March 5, 2018, they have granted 4,130,770 stock options as part of a Company-wide long-term incentive plan. The goal of the grant is to align the interest of all employees with those of shareholders. 2,381,944 options have been granted to four officers, one of whom is also a director. Independent directors di

Feb 27, 2018 08:00 am ET

SQI Diagnostics and Predictive Health Diagnostics Announce Launch of Revolutionary Predictive Cardiac Test

TORONTO, Feb. 27, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI"), and Predictive Health Diagnostics Co., ("PHD") an Irvine, CA-based pioneer in the field of predictive diagnostic medicine, today announced the validation, commercial transition, and successful installation of SQI's automated sqidlite™ system to run PHD's multi-biomarker cardiac event prediction assay in PHD's CLIA laboratory in Irvine,

Feb 27, 2018 08:00 am ET

SQI Diagnostics and Predictive Health Diagnostics Announce Launch of Revolutionary Predictive Cardiac Test

TORONTO, Feb. 27, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI"), and Predictive Health Diagnostics Co., ("PHD") an Irvine, CA-based pioneer in the field of predictive diagnostic medicine, today announced the validation, commercial transition, and successful installation of SQI's automated sqidlite™ system to run PHD's multi-biomarker cardiac event prediction assay in PHD's CLIA laboratory in

Feb 05, 2018 07:00 am ET

SQI Diagnostics Reports First Quarter 2018 Results

TORONTO, Feb. 5, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three months ended December 31, 2017.

Feb 05, 2018 07:00 am ET

SQI Diagnostics Reports First Quarter 2018 Results

TORONTO, Feb. 5, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three months ended December 31, 2017.

Jan 23, 2018 02:46 pm ET

SQI Diagnostics to Announce First Quarter 2018 Results

TORONTO, Jan. 23, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three months ended December 31, 2017 at 8:00 a.m. ET Monday, February 5, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Monday, February 5, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Jan 23, 2018 02:46 pm ET

SQI Diagnostics to Announce First Quarter 2018 Results

TORONTO, Jan. 23, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three months ended December 31, 2017 at 8:00 a.m. ET Monday, February 5, 2018. President and CEO, Andrew Morris, along with Company management, will host a conference call on Monday, February 5, 2018 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Jan 17, 2018 03:30 pm ET

SQI Signs Agreement with a Global Biotechnology Company

TORONTO, Jan. 17, 2018 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced it has signed a revenue-producing agreement with a global biotechnology company to provide assay development and future sample testing and analysis services.

Jan 17, 2018 03:30 pm ET

SQI Signs Agreement with a Global Biotechnology Company

TORONTO, Jan. 17, 2018 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), today announced it has signed a revenue-producing agreement with a global biotechnology company to provide assay development and future sample testing and analysis services.

Dec 20, 2017 04:00 pm ET

Ad blocking detected

SQI Diagnostics Inc. (V:SQD.H)

Business Focus: Advanced Medical Equipment & Technology (NEC)